Skip to content
OpenCapital
Get started
Ocular Therapeutix logo

Ocular Therapeutix (OCUL) Q1 2026 Earnings

OCUL·Reported May 5, 2026·Before market open

Ocular Therapeutix reported Q1 2026 revenue of $10.8M (+1.4% YoY), missed analyst consensus of $12.7M by $1.9M. Diluted EPS came in at $-0.41 (-10.8% YoY), missed the $-0.32 consensus by $0.09.

Revenue
$10.8Mmissed by $1.9M
Consensus: $12.7M
Diluted EPS
$-0.41missed by $0.09
Consensus: $-0.32
SEC

SEC Filings

Earnings release8-K · 0001104659-26-055241
Quarterly report10-Q · 0001104659-26-055256

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Ocular Therapeutix's Q1 2026 earnings report.

Ocular Therapeutix (OCUL) reported Q1 2026 earnings on May 5, 2026 before market open.

Ocular Therapeutix reported revenue of $10.8M and diluted EPS of $-0.41 for Q1 2026.

Revenue missed the consensus estimate of $12.7M by $1.9M. EPS missed the consensus estimate of $-0.32 by $0.09.

Compared to the same quarter a year prior, revenue grew 1.4% from $10.6M a year earlier and diluted EPS declined 10.8% from $-0.37.

You can read the 8-K earnings release (0001104659-26-055241) and the 10-Q periodic report (0001104659-26-055256) directly on SEC EDGAR. The filing index links above go to sec.gov.